BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.53 USD
0.00 (-0.39%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $0.52 -0.01 (-1.87%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLRX 0.53 0.00(-0.39%)
Will BLRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BLRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BLRX
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Buy Rating Affirmed for Bioline RX on Promising Motixafortide Trial Results
Biotech Alert: Searches spiking for these stocks today
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide